A panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. Highlights include techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered.
"synopsis" may belong to another edition of this title.
The highly significant role that acquired genetic abnormalities play in the genesis, diagnosis, and management of hematological malignancies has become increasingly clear. Such abnormalities can serve as useful markers for initial diagnosis, accurate subclassification, and the evaluation of minimal residual disease, as well as providing critical targets for novel therapies. In Myeloid Leukemia: Methods and Protocols, a panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. The methods range from those that are of immediate clinical relevance to the investigation and management of patients with myeloid malignancies, to those that relate to recently identified genetic abnormalities of potential clinical significance. Highlights include techniques for thedetection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered. The protocols follow the successful Methods in Molecular Biology™ series format, each offering step-by-step laboratory instructions, an introduction outlining the principles behind the technique, lists of the necessary equipment and reagents, and tips on troubleshooting and avoiding known pitfalls.
Clinically relevant and highly practical, Myeloid Leukemia: Methods and Protocols offers cytogeneticists, hematologists, and oncologists cutting-edge laboratory techniques that can be rapidly implemented for the investigation and management of patients with myeloid malignancies.
"About this title" may belong to another edition of this title.
Seller: Brook Bookstore On Demand, Napoli, NA, Italy
Condition: new. Questo è un articolo print on demand. Seller Inventory # 1098948c8c2acc2ef40c451a94c4d2b5
Quantity: Over 20 available
Seller: moluna, Greven, Germany
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Includes supplementary material: sn.pub/extrasA panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number. Seller Inventory # 448152843
Quantity: Over 20 available
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -A panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. Highlights include techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered. 320 pp. Englisch. Seller Inventory # 9781607614562
Seller: preigu, Osnabrück, Germany
Taschenbuch. Condition: Neu. Myeloid Leukemia | Methods and Protocols | Harry Iland (u. a.) | Taschenbuch | Methods in Molecular Medicine | xi | Englisch | 2020 | Humana | EAN 9781607614562 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Seller Inventory # 101493086
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - A panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. Highlights include techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered. Seller Inventory # 9781607614562
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -A panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. Highlights include techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 320 pp. Englisch. Seller Inventory # 9781607614562
Seller: Books Puddle, Woodside, NY, U.S.A.
Condition: New. 320 Reprint edition NO-PA02APR2015-KAP. Seller Inventory # 26372064015
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: Brand New. reprint edition. 318 pages. 9.01x5.98x0.76 inches. In Stock. Seller Inventory # zk1607614561
Quantity: 1 available
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. Print on Demand 320. Seller Inventory # 375029968
Quantity: 4 available
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. PRINT ON DEMAND 320. Seller Inventory # 18372064005